E-Posters-10189

Pdf Summary

A pilot investigation called URGE aimed to explore the association between metabolizer status and the effectiveness and adverse events of fesoterodine therapy in women over 50 years with urge urinary incontinence (UUI). Fesoterodine is an anticholinergic medication used to treat UUI. The study objective was to assess whether pharmacogenetics, specifically metabolizer status, could help individualize therapy for UUI treatment.<br /><br />The study involved women over 50 years old who had at least three episodes of UUI per day. They were given fesoterodine therapy for four weeks, starting with a dose of 4mg for the first two weeks and then 8mg for the next two weeks. After the four-week period, the researchers assessed the women based on their response to the treatment and the occurrence of moderate to severe adverse events.<br /><br />Peripheral blood samples were collected to determine the participants' metabolizer status. The metabolizer status refers to the ability of the CYP2D6 enzyme to metabolize fesoterodine. It can be categorized as poor, intermediate, extensive, or ultrarapid. In this study, the focus was on comparing extensive metabolizers (EM) and poor metabolizers (PM).<br /><br />The key findings of the investigation revealed that metabolizer status was not associated with the effectiveness of fesoterodine or the occurrence of moderate to severe adverse events. However, it was noted that the proportion of poor metabolizers in the study population was lower than expected.<br /><br />The researchers concluded that further research is needed, including larger and well-powered studies, to better understand the individualization of UUI treatment through genetic evaluation. They also emphasized the importance of continued evaluation of methods to personalize therapy for UUI.

Meta Tag

Concept Overactive Bladder

Concept Urinary Incontinence

Concept Fesoterodine

Concept CYP2D6

Concept Antimuscarinic Agents

Keywords

URGE

metabolizer status

effectiveness

adverse events

fesoterodine therapy

women over 50 years

urge urinary incontinence

anticholinergic medication

pharmacogenetics

UUI treatment

Overactive Bladder

Urinary Incontinence

Fesoterodine

CYP2D6

Antimuscarinic Agents